Checkout
Please register your details and proceed to checkout.
Type 2 Diabetes Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Biguanides, Sulfonylureas, Meglitinides, Thiazolidinediones (TZDs), Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, Alpha-Glucosidase Inhibitors; By Product Type; By Treatment Type; Key Players
Corporate License
$ 4499.00
Total Price: $ 4499.00
We use cookies, just to track visits to our website, we store no personal details. Privacy PolicyX
Reports
Press Release
Blogs
Price Forecast